AbbVie Inc.

The $10.9 billion acquisition of Apogee Therapeutics is seen as a strategically sound move that strengthens AbbVie's immunology pipeline in atopic dermatitis and asthma. Canaccord raised its price target to $273, and Piper Sandler to $298, both highlighting undervalued R&D opportunities and long-term growth alignment.

TD Cowen and other analysts consider the $10.9 billion price tag steep, questioning the deal's timing relative to critical trial milestones. Clear Street and RBC Capital warn that AbbVie is entering an atopic dermatitis market crowded with established and emerging competitors like Regeneron, raising doubts about long-term value realization.

BMO Capital raised its price target to $300, citing Skyrizi's continued revenue durability in Q2 2026 with limited competitive pressure despite the launch of rival therapy Icotyde. RBC Capital, Wells Fargo, Bank of America, HSBC, and Cantor Fitzgerald also raised targets, all citing AbbVie's immunology franchise strength as a key driver.

AbbVie's story could be derailed if key immunology bets underperform or pricing pressure compresses already modest profit margins. Net income margin has already compressed from 7.59% in 2024 to 6.9% in 2025, and competitive threats from established players in immunology pose significant headwinds for long-term holders.

The most widely followed valuation narrative pegs AbbVie's fair value at $253.55 per share, closely aligned with its recent trading price. Analysts project earnings to reach $22.7 billion by June 2029, up from $3.6 billion today, supported by long-term revenue growth of nearly 8% and a robust pipeline across immunology and neuroscience.

AbbVie's current P/E of approximately 125x stands dramatically above the US biotech industry average of 17.3x, the peer average of 22.5x, and even its own estimated fair ratio of 43.8x. This extreme premium leaves virtually no margin for error, making the stock highly vulnerable to any pipeline disappointment or margin compression.